Modalis Therapeutics Corporation (JP:4883)
:4883
Want to see JP:4883 full AI Analyst Report?
Top Page
Modalis Therapeutics Corporation
(4883)
Select Model
Select Model
Rating:47Neutral
Price Target:
¥65.00
▲(16.07% Upside)
Action:ReiteratedDate:05/02/26
The score is primarily weighed down by very weak financial performance (minimal revenue, large losses, and sustained cash burn with shrinking equity). Technicals are moderately supportive (price above key moving averages and positive MACD) but tempered by an overbought RSI. Valuation remains challenging due to negative earnings and no dividend yield data.
Positive Factors
Conservative balance sheet leverage
Zero reported debt in 2024–2025 materially reduces fixed financing costs and bankruptcy risk, giving management durable optionality to fund R&D via equity or partnerships. Low leverage preserves strategic flexibility during lengthy drug development cycles.
Negative Factors
Minimal-to-zero revenue
Sustained absence of product revenue means the business remains pre-commercial and must rely on successful R&D or external financing to reach sustainable operations. This elevates execution risk and prevents internal funding of development or commercialization over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet leverage
Zero reported debt in 2024–2025 materially reduces fixed financing costs and bankruptcy risk, giving management durable optionality to fund R&D via equity or partnerships. Low leverage preserves strategic flexibility during lengthy drug development cycles.
Read all positive factors
Modalis Therapeutics Corporation (4883) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.34B
Dividend YieldN/A
Average Volume (3M)719.68K
Price to Earnings (P/E)―
Beta (1Y)0.03
Revenue GrowthN/A
EPS Growth9.50%
CountryJP
Employees14
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-24.01
Shares Outstanding96,134,094
10 Day Avg. Volume617,120
30 Day Avg. Volume719,680
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.2
Revenue Forecast (FY)¥800.00M
Modalis Therapeutics Corporation Business Overview & Revenue Model
Company Description
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to...
How the Company Makes Money
null...
Modalis Therapeutics Corporation Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
54
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 40.50M | 1.10M |
| Gross Profit | -583.00K | 0.00 | 0.00 | -731.00K | -83.17M | 1.10M |
| EBITDA | -2.33B | -2.21B | -2.15B | -2.37B | -2.58B | -667.55M |
| Net Income | -1.56B | -2.15B | -1.32B | -2.39B | -2.70B | -738.96M |
Balance Sheet | ||||||
| Total Assets | 3.42B | 2.96B | 3.69B | 2.03B | 3.13B | 6.07B |
| Cash, Cash Equivalents and Short-Term Investments | 3.26B | 2.81B | 3.58B | 1.88B | 2.93B | 4.94B |
| Total Debt | 0.00 | 0.00 | 0.00 | 412.50M | 0.00 | 0.00 |
| Total Liabilities | 228.82M | 170.94M | 143.47M | 645.50M | 188.60M | 519.92M |
| Stockholders Equity | 3.19B | 2.79B | 3.55B | 1.38B | 2.94B | 5.55B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.12B | -1.43B | -2.29B | -2.09B | -854.58M |
| Operating Cash Flow | 0.00 | -2.12B | -1.43B | -2.25B | -1.90B | -747.47M |
| Investing Cash Flow | 0.00 | -2.57M | -188.00K | -39.70M | -185.72M | 171.56M |
| Financing Cash Flow | 0.00 | 1.35B | 3.04B | 1.22B | 63.68M | 72.63M |
Modalis Therapeutics Corporation Technical Analysis
Negative
56.00
Price Trends
57.04
Negative
59.03
Negative
71.11
Negative
Market Momentum
-1.09
Positive
42.08
Neutral
30.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4883, the sentiment is Negative. The current price of 56 is below the 20-day moving average (MA) of 56.05, below the 50-day MA of 57.04, and below the 200-day MA of 71.11, indicating a bearish trend. The MACD of -1.09 indicates Positive momentum. The RSI at 42.08 is Neutral, neither overbought nor oversold. The STOCH value of 30.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4883.
Modalis Therapeutics Corporation Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥14.62B | 14.74 | ― | ― | 1.67% | 2.66% | |
64 Neutral | ¥6.07B | 11.64 | ― | 3.21% | 1.67% | ― | |
55 Neutral | ¥8.74B | -13.67 | -90.96% | ― | 36.19% | 60.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥6.84B | -12.20 | ― | ― | 324.27% | 18.93% | |
47 Neutral | ¥6.34B | -3.55 | ― | ― | ― | 9.50% | |
43 Neutral | ¥6.98B | -0.93 | ― | ― | -46.69% | -12.40% |
* Healthcare Sector Average
JP:4883
Modalis Therapeutics Corporation
64.00
-9.00
-12.33%
JP:4597
Solasia Pharma KK
32.00
0.00
0.00%
JP:4539
Nippon Chemiphar Co., Ltd.
1,670.00
224.14
15.50%
JP:4574
Taiko Pharmaceutical Co., Ltd.
293.00
15.00
5.40%
JP:4582
Symbio Pharmaceuticals Limited
93.00
-65.00
-41.14%
JP:4892
Cyfuse Biomedical K.K.
681.00
-296.00
-30.30%
Modalis Therapeutics Corporation Corporate Events
Modalis Sells Idle U.S. Equipment, Books Extraordinary Gain on Asset Transfer
Apr 27, 2026
Modalis Therapeutics’ U.S. subsidiary in Waltham, Mass., has decided to transfer machinery and equipment that have become idle following the completion of their intended roles in process development, as part of a broader effort to improve ma...
Modalis Sets Terms for 18th Stock Option Plan, Issuing 935,000 Potential Shares
Apr 14, 2026
Modalis Therapeutics has set the detailed terms for its 18th stock option program, confirming an exercise price of 6,100 yen per unit, equivalent to 61 yen per share, calculated as the higher of a 5% premium over the prior month’s average cl...
Modalis Therapeutics Issues 18th Series Stock Options to Align Incentives and Retain Talent
Mar 26, 2026
Modalis Therapeutics has approved the issuance of its 18th series of stock options, granting 9,450 share acquisition rights to 21 grantees, including three directors and employees of the company and its subsidiary. The options, issued free of char...
Modalis Outlines FY2025 Growth Plans in Confidential TSE-Mandated Update
Mar 25, 2026
Modalis Therapeutics Corporation released its FY2025 year-end business plan update, outlining matters related to its growth potential and operational outlook. The company emphasized that the materials are for informational purposes only, may chang...
Modalis Therapeutics Seeks Approval for Virtual-Ready Shareholder Meetings
Feb 20, 2026
Modalis Therapeutics plans to amend its Articles of Incorporation to allow shareholders’ meetings to be held without a designated physical location, following a resolution by its Board of Directors. The proposal, driven by recent legal chang...
Modalis to Wipe Out Retained Earnings Deficit via Capital Reduction
Feb 20, 2026
Modalis Therapeutics plans to restructure its equity accounts by reducing its stated capital by ¥1,124,612,444 and its capital reserves by ¥1,124,612,443, reallocating these amounts to other capital surplus. The move is aimed at repairin...
Modalis Slows IND Timeline for Lead CRISPR Program as It Strengthens Clinical Readiness
Feb 12, 2026
Modalis Therapeutics reported continued progress in preparing its lead candidate MDL-101 for clinical trials, citing consistent survival benefits in disease model mice and no new safety concerns, while conducting further analyses to refine develop...
Modalis Loss Widens on Higher R&D Spend Amid Zero Revenue in FY2025
Feb 12, 2026
Modalis Therapeutics has reported a widening loss for the fiscal year ended December 31, 2025, with consolidated operating income falling to a deficit of ¥2,211 million and profit attributable to owners of the parent deepening to a loss of &#...
Modalis Books Foreign Exchange Gain for FY2025 on Currency Revaluation
Feb 12, 2026
Modalis Therapeutics Corporation reported non-operating income of ¥10 million in foreign exchange gains for the fiscal year ended December 31, 2025, driven mainly by the revaluation of its foreign currency-denominated assets and liabilities a...
Modalis Issues FY2025 Report With Strict Confidentiality and Risk Disclaimers
Feb 12, 2026
Modalis Therapeutics Corporation released an English reference version of its business and financial report for the fiscal year ending in 2025, dated February 12, 2026, clarifying that the Japanese version remains the authoritative document. The c...
Modalis posts wider losses in 2025, with no revenue and no 2026 guidance
Feb 12, 2026
Modalis Therapeutics reported no operating revenue for the fiscal year ended December 31, 2025, and widened its consolidated loss, with operating income at a loss of ¥2,211 million and profit attributable to owners of parent at a loss of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.